A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
Status:
Not yet recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site
of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. The purpose
of this study is to investigate the safety/tolerability and the pharmacokinetic(PK) profile
of HS-10382 in patients with chronic myeloid leukemia (CML). Anti-CML activity will also be
investigated in this study.